Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
'For people with severe Long Covid, travel can be dangerous,' said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. 'LoCITT enables even patients with the most severe symptoms to join the search for answers.'
The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic.
'Decentralized trials broaden reach, speed timelines and yield richer real-world evidence,' said Vik Kheterpal, MD, a principal at CareEvolution. 'LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid.'
Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data.
'For people with severe Long Covid, travel can be dangerous,' said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. 'LoCITT enables even patients with the most severe symptoms to join the search for answers.' Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol.
Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings.
'We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it,' said John Redd, CEO of SILC. 'We're hopeful that a remote trial will help us find effective treatments more quickly.'
CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data.
CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT.
Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at longcovid.scripps.edu to be notified when the Scripps clinical trial opens.
About CareEvolution
We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit careevolution.com.
About the Schmidt Initiative for Long Covid
The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit https://silc.org/.
About Scripps Research
Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
05-08-2025
- Medscape
Long COVID and Returning to Work: A Hard, Frustrating Road
Many patients with long COVID, struck down by the condition on the job, remain out of work and are still waiting on the finalization of workers' compensation claims. Several new studies suggested the problem may be striking more workers than previously estimated. Around 16 million workers have been affected nationwide by long COVID. Many who initially contracted the virus as a result of their jobs are left with the additional burden of proving that they acquired the condition in the workplace. Without it, they may be unable to file a claim for workers' compensation insurance, which provides benefits to employees who are injured or become ill on the job. Patients with long COVID are costly because they see doctors more often and are less likely to have their claims covered by workers' compensation insurance. Experts contend that, in order for claims to be covered by insurance, physicians need standardized diagnostic tests to prove patients have the condition as well as FDA-approved treatments that insurance companies are more likely to cover, and regulations that mandate coverage either federally or at the state level. This way, patients can get the care they need to return to work. Many Workers Sickened on the Job In states like California, patients with long COVID claims made up 5% of all California workers' compensation claims but accounted for a whopping 82% of medical treatment dollars. In New York, an analysis from the New York State Insurance Fund found more than 3100 workers' compensation claims, and among them, 18% were unable to work for more than a year because of ongoing long COVID symptoms. In all, around 6% of workers' compensation claims nationwide have been for long COVID, but many of these patients have had trouble collecting benefits. An additional 4% of Medicare patients, a large percentage of whom are retired, have been diagnosed and not recovered from long COVID. Many patients may have been close to retirement and decided to retire after a struggle to get better. 'In California alone, long COVID workers' compensation claims have cost upwards of $350.6 million, and it's only going to get worse,' said Grace McComsey, MD, who leads one of the 15 nationwide long COVID centers funded by the federal Researching COVID to Enhance Recovery Initiative in Cleveland. McComsey said that treatments will remain costly without more research to solve the problem of long COVID for the millions of workers who remain sick and can't go back to work. Charlie McCone, 35, of San Francisco, is one of those patients. He lost his job due to long COVID and now depends on his partner financially. He said he's seen upwards of 30 physicians and goes to the doctor weekly, and more recently, monthly, in an effort to find effective treatments for his debilitating condition. 'As somebody who has never had any health problems before, you go from interacting with the healthcare system once a year to weekly,' said McCone. 'It's why long COVID patients are so costly.' McCone has yet to receive any disability benefits for his condition. Tina Ridler, of Rochester, Minnesota, has been living with long COVID after a serious bout with acute COVID-19 in 2020. She went from working 60-80 hours weekly as a self-employed wellness center owner to a maximum of 20 hours. 'When you're already sick, it's scary to watch your access to treatment in flux,' said Ridler. At 60 years old, she's on the cusp of retirement, but with so many bills to pay, she's constantly financially stressed. Patients Need Standardized Diagnostic Tests Many of the patients filing workers' compensation claims were in healthcare and consumer-facing businesses, such as workers in the restaurant and airline industries, said Nisha Viswanathan, MD, director of the University of California, Los Angeles Long COVID Program. Long COVID is still a 'diagnosis of exclusion,' so in order for patients to gain coverage, physicians must do a number of tests to rule out other undiagnosed medical conditions to help prove that long COVID is causing their symptoms. 'While I'm glad that these patients are getting recognition that their long COVID was a result of their jobs, I still see a lot of struggles,' said Viswanathan. Workers' compensation companies have been pushing back on paying patient bills because there aren't any diagnostic tests for long COVID, and workups for patients can be costly, and often, they're still not covered, said Viswanathan. FDA-Approved Treatments Are More Likely Covered Viswanathan said that there's no incentive for workers' compensation companies to pay for treatments that they deem experimental and costly, which can be problematic when there are no FDA-approved long COVID treatments. A mandate of some sort of coverage at the state or federal level would also be helpful to protect patients, she added. Treatments like low-dose naltrexone, which Viswanathan has found helpful for some of her patients suffering from pain, sleep issues, and fatigue, for example, aren't approved long COVID treatments, and therefore, patients must pay for them out-of-pocket. 'What we really need are studies that validate treatments so that commercial insurance and workers' compensation companies will cover them,' said Viswanathan. That's been a chicken-and-egg problem from the start because without research dollars, patients can't secure approved treatments, and without approved treatments, patients can't get better and go back to work full-time. At the same time, the Trump Administration has slashed research funding along with access to treatments. In March, it closed the federal government's Office of Long COVID Research and Practice as part of a larger restructuring of health agencies. Additionally, its 2026 budget plan included a 40% cut in National Institutes of Health spending and a 55% cut in the National Science Foundation budget. Older Workers and Retirees Hit Hard A study published in The Journals of Gerontology found that of 3,588,671 Medicare recipients, nearly 4%, or 140,000 patients, had been diagnosed with long COVID and had their symptoms for over a year. Medicare does cover treatments for long COVID, though not all patients have access to the specialists required for treatment. According to the research, long COVID diagnoses in Medicare claims were common in a large sample of older adults. For David Putrino, PhD, a national leader in the treatment of long COVID at Mount Sinai Health System in New York City, it shows that older patients are still struggling. Many patients likely chose to retire because of their health. 'The Medicare numbers are eye- catching,' said Putrino. For physicians and patients alike, there's a frustration that patients can't get back to normal life because they're not able to get better, and at the same time, the cost for their treatments is mounting. 'Understanding how costly this disease is, we should be all-in when it comes to researching effective treatments,' said McComsey.
Yahoo
05-08-2025
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
05-08-2025
- Business Wire
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. 'For people with severe Long Covid, travel can be dangerous,' said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. 'LoCITT enables even patients with the most severe symptoms to join the search for answers.' The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. 'Decentralized trials broaden reach, speed timelines and yield richer real-world evidence,' said Vik Kheterpal, MD, a principal at CareEvolution. 'LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid.' Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. 'For people with severe Long Covid, travel can be dangerous,' said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. 'LoCITT enables even patients with the most severe symptoms to join the search for answers.' Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. 'We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it,' said John Redd, CEO of SILC. 'We're hopeful that a remote trial will help us find effective treatments more quickly.' CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at
